Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3062% above fair value
$105.43−1.68 (-1.57%)
Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –
Edwards Lifesciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Edwards Lifesciences's operating cash flow for the twelve months ending Jun 30, 2026 was $1.72B, up 116.4% year over year. For fiscal 2025 it was $1.60B, up 194.2% from the year before. Over ten years it grew 11.2% a year on average. The highest annual figure on record is $1.73B in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.60B | +194.2% |
| FY2024 | Dec 31, 2024 | $542.30M | -39.5% |
| FY2023 | Dec 31, 2023 | $895.80M | -26.5% |
| FY2022 | Dec 31, 2022 | $1.22B | -29.7% |
| FY2021 | Dec 31, 2021 | $1.73B | +64.3% |
| FY2020 | Dec 31, 2020 | $1.05B | -10.9% |
| FY2019 | Dec 31, 2019 | $1.18B | +27.6% |
| FY2018 | Dec 31, 2018 | $926.70M | -7.4% |
| FY2017 | Dec 31, 2017 | $1.00B | +42.1% |
| FY2016 | Dec 31, 2016 | $704.40M | +28.1% |
| FY2015 | Dec 31, 2015 | $549.70M | -46.2% |
| FY2014 | Dec 31, 2014 | $1.02B | +116.3% |
| FY2013 | Dec 31, 2013 | $472.70M | +30.5% |
| FY2012 | Dec 31, 2012 | $362.10M | +17.5% |
| FY2011 | Dec 31, 2011 | $308.20M | +22.6% |
| FY2010 | Dec 31, 2010 | $251.40M | +52.1% |
| FY2009 | Dec 31, 2009 | $165.30M | +7.9% |
| FY2008 | Dec 31, 2008 | $153.20M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $651.90M | +124.6% |
| Q1 FY2026 | Mar 31, 2026 | $43.80M | -84.4% |
| Q4 FY2025 | Dec 31, 2025 | $450.90M | – |
| Q3 FY2025 | Sep 30, 2025 | $573.70M | +63.1% |
| Q2 FY2025 | Jun 30, 2025 | $290.20M | -21.9% |
| Q1 FY2025 | Mar 31, 2025 | $280.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$127.50M | -193.3% |
| Q3 FY2024 | Sep 30, 2024 | $351.80M | -14.5% |
| Q2 FY2024 | Jun 30, 2024 | $371.50M | +1005.7% |
| Q1 FY2024 | Mar 31, 2024 | -$53.50M | -117.0% |
| Q4 FY2023 | Dec 31, 2023 | $136.60M | -51.7% |
| Q3 FY2023 | Sep 30, 2023 | $411.50M | +32.8% |
| Q2 FY2023 | Jun 30, 2023 | $33.60M | -89.9% |
| Q1 FY2023 | Mar 31, 2023 | $314.10M | +7.1% |
| Q4 FY2022 | Dec 31, 2022 | $282.80M | -24.3% |
| Q3 FY2022 | Sep 30, 2022 | $309.90M | -41.7% |
| Q2 FY2022 | Jun 30, 2022 | $332.20M | -36.9% |
| Q1 FY2022 | Mar 31, 2022 | $293.30M | -2.4% |
| Q4 FY2021 | Dec 31, 2021 | $373.60M | -6.6% |
| Q3 FY2021 | Sep 30, 2021 | $531.90M | +146.1% |
| Q2 FY2021 | Jun 30, 2021 | $526.10M | +127.5% |
| Q1 FY2021 | Mar 31, 2021 | $300.50M | +45.1% |
| Q4 FY2020 | Dec 31, 2020 | $399.80M | -0.8% |
| Q3 FY2020 | Sep 30, 2020 | $216.10M | -50.6% |
| Q2 FY2020 | Jun 30, 2020 | $231.30M | -32.2% |
| Q1 FY2020 | Mar 31, 2020 | $207.10M | +13706.7% |
| Q4 FY2019 | Dec 31, 2019 | $402.90M | +37.6% |
| Q3 FY2019 | Sep 30, 2019 | $437.30M | +27.8% |
| Q2 FY2019 | Jun 30, 2019 | $341.20M | +143.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.50M | -99.0% |
| Q4 FY2018 | Dec 31, 2018 | $292.90M | -19.5% |
| Q3 FY2018 | Sep 30, 2018 | $342.30M | +10.1% |
| Q2 FY2018 | Jun 30, 2018 | $140.20M | -29.1% |
| Q1 FY2018 | Mar 31, 2018 | $151.30M | +17.9% |
| Q4 FY2017 | Dec 31, 2017 | $363.90M | +81.0% |
| Q3 FY2017 | Sep 30, 2017 | $310.80M | +50.9% |
| Q2 FY2017 | Jun 30, 2017 | $197.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $128.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $201.10M | – |
| Q3 FY2016 | Sep 30, 2016 | $205.90M | – |
See a number that looks wrong?